<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-14 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-14</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-14</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <p><strong>Paper ID:</strong> paper-8a248b1e0d47eb09d7b13ac3df7120f950f33632</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/8a248b1e0d47eb09d7b13ac3df7120f950f33632" target="_blank">Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Oncology</p>
                <p><strong>Paper TL;DR:</strong> The potential usefulness of neoadjuvant immunotherapy as an organ preservation strategy in mucosal melanoma deserves further evaluation in prospective clinical trials.</p>
                <p><strong>Paper Abstract:</strong> Mucosal melanoma represents an uncommon melanoma subtype. Wide excision has long represented the standard therapeutic approach. Unfortunately, there is a high relapse rate and mortality. Neoadjuvant therapy with ipilimumab plus nivolumab has shown significant activity in cutaneous melanoma. We present two cases of mucosal melanoma, each with potential regional dissemination, who were treated with neoadjuvant immunotherapy with minimal toxicity. Both patients were closely monitored and achieved radiologic and pathologic complete responses. These patients were able to avoid radical surgery and related functional consequences. Both patients remain recurrence-free with protracted follow-up. The potential usefulness of neoadjuvant immunotherapy as an organ preservation strategy in mucosal melanoma deserves further evaluation in prospective clinical trials.</p>
                <p><strong>Cost:</strong> 0.019</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e14.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e14.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SWOG 1801</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SWOG S1801 (Neoadjuvant-adjuvant vs adjuvant-only pembrolizumab trial)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A randomized phase II trial comparing neoadjuvant pembrolizumab followed by adjuvant pembrolizumab versus adjuvant-only pembrolizumab in resectable stage III/IV cutaneous melanoma; reported superior 2-year event-free survival with the neoadjuvant strategy.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Patel et al., N Engl J Med. 2023</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2023</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Randomized phase II (neoadjuvant + adjuvant vs adjuvant-only)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Neoadjuvant pembrolizumab (3 cycles over ~9 weeks) followed by surgery and adjuvant pembrolizumab versus surgery followed by adjuvant pembrolizumab (treatment durations equivalent between arms).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Potentially resectable stage IIIb to IVc cutaneous melanoma (paper does not state inclusion/exclusion for mucosal tumors in this case report).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Resectable stage IIIbâ€“IVc melanoma (as stated in the case report summary).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>154</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Pembrolizumab (neoadjuvant; exact dose/schedule described in original trial as 3 cycles over 9 weeks in this summary).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>3 cycles over ~9 weeks prior to surgery (per summary in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant pembrolizumab (duration equivalent between arms; exact duration not specified in this summary).</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td>Adjuvant pembrolizumab alone after surgery (same total planned treatment duration as neoadjuvant arm).</td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Planned surgery was only rarely delayed or omitted in the trial (no numeric rate provided in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Event-free survival reported (2-year timepoint highlighted); safety reported.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td>2-year event-free survival: neoadjuvant+adjuvant group 72% vs adjuvant-only group 49% (reported as statistically significantly higher for neo+adj).</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td>At 2 years absolute difference in event-free survival ~23 percentage points (72% vs 49%).</td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>The paper (case report) cites SWOG S1801 as evidence supporting the idea that neoadjuvant therapy improves outcomes in locoregionally advanced melanoma, but does not provide mechanistic immune data from SWOG S1801 in this report.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>The case report states that only 12% of patients receiving neoadjuvant and adjuvant ICI therapy experienced a treatment-related adverse event (no grade breakdown provided in this summary).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Surgery delays or omissions were rare in this trial summary (no numeric detail provided).</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Detailed trial-level limitations (HRs, CIs, per-arm sizes, follow-up) are not provided in this case report summary; mechanistic correlates were not described here.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report', 'publication_date_yy_mm': '2024-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e14.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN / OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN and OpACIN-neo neoadjuvant immunotherapy trials in stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase II neoadjuvant studies testing ipilimumab plus nivolumab in stage III melanoma with reported high pathologic response rates and associated improved relapse-free survival in responders; included survival and biomarker analyses (per Rozeman et al.).</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>OpACIN / OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Rozeman et al., Nat Med. 2021</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2021</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase II neoadjuvant trials with translational/biomarker analyses (several dosing schedules tested for ipilimumab + nivolumab).</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Neoadjuvant ipilimumab + nivolumab in various dosing schedules (studies evaluated pathologic response and biomarker correlates); not a randomized neoadjuvant vs adjuvant-only comparison in the summarized description.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Stage III cutaneous melanoma patients (per cited trials); mucosal melanomas not indicated in this summary.</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Stage III melanoma (trial-specific staging criteria reported in original trial publications; not detailed in this case report).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Ipilimumab + nivolumab in neoadjuvant setting (various dosing schedules; the case report references use of a modified lower-toxicity regimen elsewhere but dosing in OpACIN(-neo) is not specified here).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant therapy approaches varied; trials included response-directed subsequent therapy (details not provided in this summary).</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Planned surgery was only rarely delayed or omitted in these neoadjuvant studies (per the case report), but no rates provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Reported association: 2-year relapse-free survival for patients who achieved a pathologic response was 97% versus 36% for those without a major pathologic response (Rozeman et al., cited in this paper).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response rates, relapse-free survival (RFS), and biomarker analyses (survival and biomarker analyses referenced).</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>Reported: 2-year RFS among pathologic responders 97% vs 36% in non-major responders (as cited).</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td>For pathologic responders vs non-responders at 2 years, an absolute RFS difference reported in the summary is ~61 percentage points (97% vs 36%).</td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>The case report notes that Rozeman et al. included biomarker analyses but does not extract specific immune-correlate results (no specific TCR, TIL, IFN signatures, or antigen spreading data are provided in this case report).</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors and cited OpACIN(-neo) work support that achieving a pathologic response after neoadjuvant ICI is associated with markedly improved RFS, supporting the use of neoadjuvant therapy to induce robust antitumor immunity; however, specific mechanistic immune data are not detailed in this case report.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Reported as infrequent in the referenced neoadjuvant trials (no numeric detail in this summary).</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>This case report cites OpACIN(-neo) biomarker and outcome associations but does not provide their detailed methods or full translational tables; limits ability to evaluate specific immune mechanisms from this paper alone.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report', 'publication_date_yy_mm': '2024-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e14.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PRADO</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PRADO trial (Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A trial of neoadjuvant ipilimumab + nivolumab in high-risk stage III cutaneous melanoma employing response-directed surgery and adjuvant therapy; high rates of pathologic response correlated with excellent relapse-free survival and allowed omission of further surgery/adjuvant therapy in responders.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>PRADO</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Reijers et al., Nat Med. 2022</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase II (single-arm, response-directed) neoadjuvant study with tailored surgical/adjuvant management based on pathologic response.</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Single-arm neoadjuvant ipilimumab + nivolumab with subsequent personalized surgical and adjuvant decisions according to pathologic response.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>High-risk stage III cutaneous melanoma patients (99 patients reported in the case report summary).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>High-risk stage III melanoma (trial-specific criteria not detailed in this summary).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>99</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Neoadjuvant nivolumab plus ipilimumab (dosing schedule not specified in this case report).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant therapy was omitted for patients who achieved complete pathologic response per the response-directed design; details vary by response and are not fully specified here.</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>In PRADO many responders avoided more extensive surgery; 69 of the 71 patients with complete pathological response were able to undergo a therapeutic lymph node dissection (as reported in this summary) and further adjuvant therapy was omitted for responders.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>71 of 99 patients achieved complete pathological response (reported in this summary; ~71.7%).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>A major pathologic response category is discussed; exact numeric MPR rate not provided here, but major pathologic responders had excellent outcomes (24-month RFS cited).</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Patients with major pathologic response had a high estimated 24-month relapse-free survival (RFS) of 93% (reported in this summary).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response rates, 24-month relapse-free survival, quality-of-life outcomes reported in the trial summary referenced.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>Estimated 24-month RFS in patients with major pathologic response = 93% (per the case report summary).</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>The PRADO trial included biomarker/response-directed analyses (cited), but specific immune correlates (TCR expansion, IFN signatures, antigen spreading) are not detailed in this case report.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>PRADO is cited to support that pathologic response after neoadjuvant ipilimumab + nivolumab predicts excellent RFS and can guide de-escalation of surgery/adjuvant therapy; the case report uses this to justify neoadjuvant approaches for organ preservation.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>The case report emphasizes that planned surgery was only rarely delayed or omitted in PRADO (no specific rates provided here).</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Single-arm, response-directed design limits direct comparison to adjuvant-only strategies; the case report does not provide full translational data or randomized comparisons.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report', 'publication_date_yy_mm': '2024-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e14.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e14.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Ho et al. retrospective series</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma (Ho et al., 2022)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A retrospective review of 36 mucosal melanoma patients treated with neoadjuvant checkpoint inhibitors (mostly combination anti-PD1 + anti-CTLA4) reporting modest overall outcomes and low pathologic CR rate in this heterogeneous mucosal population.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>Ho et al. (retrospective cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Ho et al., Front Oncol. 2022</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Retrospective cohort review (n = 36) of neoadjuvant therapy in mucosal melanoma across multiple primary sites.</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Patients received PD-1 antibodies alone or in combination with ipilimumab; 78% received combination anti-PD1 + anti-CTLA4 therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>36 patients with mucosal melanoma (primary sites: anorectal 53%, urogenital 25%, head and neck 17%, esophageal 6%); 47% had node-positive disease or satellite lesions at treatment initiation.</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Resectable mucosal melanoma (heterogeneous sites and stages; detailed staging criteria not specified in this summary).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>36</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>PD-1 antibody monotherapy or PD-1 + CTLA-4 combination (78% received combination therapy); specific drugs/doses not provided in this summary.</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Six patients developed disease progression and were unable to have surgery; only 3 patients achieved a complete response and did not undergo planned surgery.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Only 3 of 36 patients achieved a complete response and did not undergo planned surgery (~8.3%), per the case report summary (the report characterizes the CR rate as unexpectedly low at 3% in one sentence; the paper text is internally inconsistent â€” the case report states 'Only 3 patients achieved a complete response' and later 'complete remission rate in this series was unexpectedly low (3%)' â€” exact numerator/percentage unclear in this summary).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Event-free survival was significantly higher for patients who achieved objective response and for patients with pathologic complete responses (no HRs provided in this summary).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Event-free survival, progression-free survival, overall survival, pathologic response rates, and toxicity (grade 3) reported in the retrospective series summary.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td>Median event-free survival was 9.2 months; 3-year progression-free survival 29% (per summary).</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td>3-year overall survival rate 55% (median OS not reached at median follow-up 37.9 months, per summary).</td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td>Median follow-up 37.9 months (reported in the summary).</td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>No detailed mechanistic immune correlates are provided in this case report summary of Ho et al.; the retrospective series itself may include limited translational data but none are detailed here.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>The retrospective series showed that pathologic CR associates with better EFS; the case report suggests variable responsiveness of mucosal melanoma and less favorable outcomes vs cutaneous melanoma with ICI, but no mechanistic immune data are provided here.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>Grade 3 toxicities were reported in 39% of patients in the retrospective series (per the case report summary).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Six patients progressed and were unable to have surgery; otherwise surgical feasibility varied (no further numeric surgical morbidity detail provided).</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td>The case report notes higher EFS among those achieving objective/pathologic responses; no detailed subgroup interaction statistics provided.</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td>This retrospective series had a low complete remission rate and relatively short median EFS (9.2 months), providing counterevidence that neoadjuvant ICI yields high CR rates in mucosal melanoma as it does in cutaneous melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Retrospective design, small heterogeneous sample, mixed single-agent and combination regimens, and unclear definitions/consistency around pathologic CR in the summary limit interpretability; the case report notes uncertainty why CR rate was low and that some patients received single-agent therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Neoadjuvant ipilimumab plus nivolumab therapy as a potential organ preservation strategy in mucosal melanoma: case report', 'publication_date_yy_mm': '2024-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <em>(Rating: 2)</em></li>
                <li>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. <em>(Rating: 2)</em></li>
                <li>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. <em>(Rating: 2)</em></li>
                <li>Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. <em>(Rating: 2)</em></li>
                <li>Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIb/IV checkMate 511 trial. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>